3 biotech executives on the year ahead: deals, drug pricing and the down market
Bio Pharma Dive
JANUARY 19, 2023
“What we’re experiencing now is the aftershock of the party that went on for the last three years,” said Ovid CEO Jeremy Levin in a BioPharma Dive panel that included former Sage head Jeff Jonas and biotech entrepreneur Greg Verdine.
Let's personalize your content